Víctor Burgueño Sandoval
Ayudante de investigación
Research group
Chemistry degree (2018) Universidad de Barcelona. Master in Molecular Biotechnology (2019) Universidad de Barcelona.
Professional network profiles
Last Publications
- Pascual-Pastó G, McIntyre B, Giudice AM, Alikarami F, Morrissey A, Matlaga S, Hofmann TJ, Burgeño-Sandoval V, Harvey K, Martinez D, Shah AC, Foster JB, Pogoriler J, Eagle RC, Carcaboso AM, Shields CL, Leahey AM and Bosse KR Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells CLINICAL CANCER RESEARCH . 30(16): 3578-3591.
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
- Cuadrado-Vilanova M, Burgeño-Sandoval V, Balaguer-Lluna L, Aschero MR, Castillo H, Liu, J, Pérez-Jaume S, Pascual-Pastó G, Gene-Olaciregui N, Gomez-Gonzalez S, Correa, G, Suñol M, Schaiquevich, P, Radvanyi, F, Lavarino C, Mora J, Català-Mora J, Chantada G and Carcaboso AM Follow-up of intraocular retinoblastoma through the quantitative analysis of conserved nuclear DNA sequences in aqueous humor from patients JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 9(1): 32-43.
Projects
- Project name:
- Immune microenvironment of retinoblastoma
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00216
- Starting - finishing date:
- 2022 - 2026
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Inhibition of the PI3K/Akt pathway in pediatric high grade and diffuse intrinsic pontine gliomas (pHGG/DIPG)
- Leader
- Angel Montero Carcaboso
- Funding entities:
- ZZZZ_O.H.S.J.D.-Curia Provincial
- Code
- BECA BOMBERS 2019
- Starting - finishing date:
- 2020 - 2023
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.